Related Experiment Video
Updated: Aug 5, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Development of the First YTHDC1 Degrader with Improved Antileukemia Activity
Zhongpao Xie1, Yuanyuan Zhang1, Weicai Song1
1State Key Laboratory of Metabolism and Regulation in Complex Organisms, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China.
Researchers developed XY-2, the first PROTAC molecule targeting YTHDC1, to treat acute myeloid leukemia (AML). This novel degrader effectively eliminates YTHDC1, inhibiting cancer cell growth and offering a promising new therapeutic strategy for AML patients.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- N-Methyladenosine (m6A) is the most common internal modification in eukaryotic mRNA.
- YTHDC1 is a key nuclear reader protein involved in acute myeloid leukemia (AML).
- Targeted degradation of YTHDC1 for AML therapy remains unexplored.
Purpose of the Study:
- To design and synthesize the first PROTAC molecule targeting YTHDC1.
- To evaluate the therapeutic potential of YTHDC1 degradation in AML.
Main Methods:
- Rational design and synthesis of a PROTAC molecule (XY-2) based on YTHDC1 crystal structure.
- Assessment of YTHDC1 degradation efficiency in AML cell lines (MOLM13, Kasumi-1).
- Evaluation of XY-2's functional effects on AML cell proliferation, migration, invasion, and apoptosis.
- Transcriptomic analysis to identify downstream molecular mechanisms.
Main Results:
- XY-2 induced proteasome-dependent YTHDC1 degradation at low nanomolar concentrations (DC50 ~11-13 nM).
- XY-2 significantly inhibited AML cell proliferation, migration, and invasion, while promoting apoptosis.
- XY-2 demonstrated superior potency compared to the parent inhibitor.
- Transcriptomic analysis revealed downregulation of cell cycle, DNA replication, and mitotic genes, causing G1 phase arrest.
Conclusions:
- XY-2 is the first highly efficient YTHDC1 degrader.
- Targeted degradation of YTHDC1 represents a promising therapeutic strategy for AML.
- XY-2 exhibits significant anti-leukemic activity and warrants further investigation for AML treatment.
